bullish
SanBio (4592 JP): Better-Than-Expected Operating Loss in FY23; Product Approval Expected in FY24
445 Views17 Mar 2023 18:14
SUMMARY
- SanBio Co Ltd (4592 JP) recorded operating loss of ¥7.9B for FY23, better than guidance of ¥8.1B. For FY24, the company guided for operating loss of ¥4.6B, in-line with consensus.
- SanBio’s cash position improved with cash and cash equivalents of ¥6.7B at the end of FY23, up from ¥4.6B at the end of the previous fiscal year.
- The company aims to obtain approval of its lead candidate SB623 as a treatment for chronic motor deficit from traumatic brain injury during the current fiscal year.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- SanBio (4592 JP): Better-Than-Expected Operating Loss in FY23; Product Approval Expected in FY2417 Mar 2023
- SanBio (4592 JP): Remains Unlucky for Second-Time; Delay in First Product Approval Weighs Heavily02 Nov 2022
- SanBio (4592 JP): Marketing Approval of First Product Expected This Year in Japan15 Apr 2022
x